share_log

Smartkem Closes $7.65 Million Offering

Smartkem Closes $7.65 Million Offering

Smartkem完成765萬美元的融資
PR Newswire ·  12/23 20:05

MANCHESTER, England, Dec. 23, 2024 /PRNewswire/ -- Smartkem (Nasdaq: SMTK), which is seeking to change the world of electronics using its disruptive organic thin-film transistors (OTFTs), announced it has completed its previously announced concurrent public and private offerings of its securities, including shares of its common stock and common stock equivalents, for an aggregate total gross proceeds of $7.65 million.

英國曼徹斯特,2024年12月23日 /PRNewswire/ -- Smartkem(納斯達克:SMTK)正在尋求通過其顛覆性的有機薄膜晶體管(OTFTs)改變電子產品的世界,宣佈已完成其之前宣佈的同時公開和私募證券的發行,包括普通股及普通股等價物,總的毛收入爲765萬美元。

Smartkem issued 1,449,997 registered shares of common stock and unregistered Class D warrants to purchase up to 1,449,997 shares of common stock to investors in concurrent public and private offerings at a price of $3.00 per share and related Class D warrant. Each investor received one Class D warrant for each share purchased in the public offering.

Smartkem 向投資者發行了 1,449,997 股註冊的普通股和未註冊的 D 類權證,以購買最多 1,449,997 股普通股,這些證券的價格爲每股 3.00 美元和相關的 D 類權證。每位投資者在公開發行中每購買一股普通股就獲得一個 D 類權證。

Pursuant to the separate concurrent private placement, the Company sold to certain institutional investors, including existing investors in the Company, 169,784 unregistered shares of common stock, unregistered pre-funded warrants to purchase up to 930,215 shares of common stock and unregistered Class D warrants to purchase up to 1,099,999 shares of common stock at a price of $3.00 per share and related Class D warrant and a price of $2.9999 per pre-funded warrant and related Class D warrant.  Each investor received one Class D warrant for each share of common stock or pre- funded warrant purchased in the offering.

根據單獨的同時定向增發,公司向某些特定機構投資者(包括公司現有投資者)出售了 169,784 股未註冊的普通股,未註冊的預資權證可購買最多 930,215 股普通股,以及未註冊的 D 類權證可購買最多 1,099,999 股普通股,售價爲每股 3.00 美元及相關的 D 類權證,和每個預資權證售價爲 2.9999 美元及相關的 D 類權證。每位投資者在發行中每購買一股普通股或預資權證就獲得一個 D 類權證。

The Class D warrants are immediately exercisable at an exercise price of $3.00 per share and expire on December 31, 2025.  The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per share and may be exercised at any time until all of the pre-funded warrants have been exercised in full.

D 類權證可以立即以每股 3.00 美元的行使價行使,並將在2025年12月31日到期。預資權證可以立即以每股 $0.0001 的行使價行使,並可以在所有預資權證已全部行使之前的任何時間行使。

The gross proceeds of the offerings described above were $7.65 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds of the offerings for working capital and general corporate purposes.

上述發行的毛收益爲765萬美元,未扣除公司需支付的承銷代理費用及其他發行費用。公司打算將發行的淨收益用於運營資本和一般企業用途。

Craig-Hallum Capital Group LLC acted as the Company's exclusive placement agent for the offerings.

Craig-Hallum Capital Group LLC 擔任公司的獨家承銷代理,並負責此次發行。

In connection with the offerings described above, the Company has entered into a registration rights offering pursuant to which it has agreed to register the shares of common stock issued in the private placement, the shares of common stock issuable upon the exercise of the Class D warrants and the pre-funded warrants sold in the offerings and certain other securities for resale by the holders thereof no later than the earlier of (i) the 10th day after the filing of the Company's annual report on Form 10-K for the year ended December 31, 2024 or (ii) April 25, 2025.

關於上述發行事項,公司已簽署了一項註冊權利發行,根據該協議,公司同意註冊在定向增發中發行的普通股、因行使D類Warrants而可發行的普通股及在發行中出售的預資金Warrants,以及其他某些證券,使其持有者在不遲於以下時間內進行轉售:(i) 截至2024年12月31日的公司年度報告在10-K表格中提交後的第10天,或(ii) 2025年4月25日。

The sale of the registered shares of common stock was made pursuant to Smartkem's effective shelf registration statement on Form S-3 (file no. 333- 281608), including a base prospectus, filed with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on August 22, 2024 and a prospectus supplement dated December 18, 2024 filed with the SEC. Copies of the prospectus supplement and the accompanying base prospectus may be obtained from Craig-Hallum Capital Group LLC, Attention: Equity Capital Markets, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, by telephone at (612) 334-6300 or by email at [email protected]. Alternatively, copies of the prospectus supplement and the accompanying base prospectus may be obtained for free at the SEC's EDGAR website at www.sec.gov.

已註冊的普通股的銷售是根據Smartkem有效的S-3表格貨架註冊聲明(文件編號333-281608)進行的,包括一份基礎招股書,該聲明已向美國證券交易委員會("SEC")提交併於2024年8月22日生效,並且在2024年12月18日提交了補充招股書。補充招股書及其附帶的基礎招股書的複製件可以向Craig-Hallum Capital Group LLC申請,聯繫方式:股票資本市場,222 South Ninth Street, Suite 350, Minneapolis, MN 55402,電話 (612) 334-6300 或通過電子郵件 [email protected]。另外,補充招股書及其附帶的基礎招股書的複製件也可以在SEC的EDGAR網站www.sec.gov上免費獲取。

This press release does not constitute an offer to sell or the solicitation of an offer to buy any Smartkem securities.

本新聞稿不構成出售任何Smartkem證券的要約或購買任何Smartkem證券的邀約。

About Smartkem

關於Smartkem

Smartkem is seeking to reshape the world of electronics with its disruptive organic thin-film transistors (OTFTs) that have the potential to revolutionize the display industry.  Smartkem's patented TRUFLEX liquid semiconductor polymers can be used to make a new type of transistor that can be used in a number of display technologies, including next generation microLED displays. Smartkem's organic inks enable low temperature printing processes that are compatible with existing manufacturing infrastructure to deliver low-cost displays that outperform existing technology.

Smartkem致力於通過其顛覆性的有機薄膜晶體管(OTFTs)重新塑造電子產品的世界,這些晶體管有潛力顛覆顯示行業。Smartkem的專利TRUFLEX液態半導體聚合物可以用來製造一種新型晶體管,並可以應用於多種顯示技術,包括下一代microLED顯示器。Smartkem的有機墨水使低溫打印工藝成爲可能,與現有製造行業相兼容,從而提供低成本的顯示器,性能優於現有技術。

Smartkem develops its materials at its research and development facility in Manchester, UK and provides prototyping services at the Centre for Process Innovation (CPI) at Sedgefield, UK. It has a field application office in Taiwan. The company has an extensive IP portfolio including 138 granted patents across 18 patent families, 16 pending patents and 40 codified trade secrets.

Smartkem在英國曼徹斯特的研發設施中開發其材料,並在英國塞季菲爾德的過程創新中心(CPI)提供原型服務。公司在臺灣設有現場應用辦公室。該公司擁有廣泛的知識產權組合,包括138項已獲批准的專利,涉及18個專利系列,16項待決專利和40項已確立的商業祕密。

Forward-Looking Statements

前瞻性聲明

All statements in this press release that are not historical are forward-looking statements, including, among other things, the expected use of proceeds received from the offerings. These statements are not historical facts but rather are based on Smartkem Inc.'s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

本新聞稿中所有非歷史性陳述均爲前瞻性陳述,包括預計將使用的發行所得款項。這些陳述不是歷史事實,而是基於Smartkem Inc.目前對其業務、運營及其他類似或相關因素的期望、估算和預測。諸如「可能」、「將」、「可以」、「會」、「應該」、「預期」、「預測」、「潛在」、「繼續」、「期望」、「打算」、「計劃」、「項目」、「相信」、「估計」等詞用於識別這些前瞻性陳述,儘管並非所有前瞻性陳述都包含這些詞。您不應對前瞻性陳述過度依賴,因爲這些陳述涉及已知和未知的風險、不確定性和假設,這些風險、不確定性和假設難以預測,有時超出公司的控制範圍。實際結果可能因多種因素而與前瞻性陳述中的結果有實質性差異,包括在公司提交給證券交易委員會的文件中描述的因素。公司沒有義務修訂或更新本聲明中的信息,以反映未來的事件或情況,即使新信息變得可用。

SOURCE SmartKem

來源 SmartKem

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論